Brainsway (NASDAQ:BWAY) Rating Lowered to Hold at Wall Street Zen

Brainsway (NASDAQ:BWAY) was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research report issued on Saturday.

BWAY has been the topic of a number of other research reports. HC Wainwright raised their target price on shares of Brainsway from $17.00 to $18.00 and gave the stock a “buy” rating in a report on Thursday. Northland Securities raised their price target on Brainsway from $19.00 to $23.00 and gave the stock an “outperform” rating in a report on Wednesday, November 12th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Brainsway in a research report on Tuesday, November 11th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, Brainsway currently has an average rating of “Moderate Buy” and a consensus price target of $20.50.

Brainsway Price Performance

Shares of BWAY opened at $15.76 on Friday. The stock has a market capitalization of $308.27 million, a PE ratio of 52.53 and a beta of 1.22. The business’s fifty day moving average price is $15.82 and its 200 day moving average price is $13.33. Brainsway has a 12-month low of $7.84 and a 12-month high of $17.92.

Brainsway (NASDAQ:BWAY) last issued its earnings results on Tuesday, November 11th. The company reported $0.08 earnings per share for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.03). Brainsway had a return on equity of 9.46% and a net margin of 12.73%.The business had revenue of $13.51 million for the quarter, compared to analyst estimates of $13.04 million. Brainsway has set its FY 2025 guidance at EPS. As a group, research analysts anticipate that Brainsway will post 0.08 earnings per share for the current fiscal year.

Institutional Trading of Brainsway

A number of institutional investors have recently made changes to their positions in the stock. Raymond James Financial Inc. bought a new position in shares of Brainsway in the second quarter valued at approximately $85,000. Trexquant Investment LP bought a new position in Brainsway during the 1st quarter valued at $129,000. NewEdge Advisors LLC increased its position in shares of Brainsway by 61.5% during the 1st quarter. NewEdge Advisors LLC now owns 19,828 shares of the company’s stock valued at $188,000 after purchasing an additional 7,549 shares during the period. Y.D. More Investments Ltd bought a new stake in shares of Brainsway in the 3rd quarter worth $263,000. Finally, Eagle Global Advisors LLC acquired a new stake in shares of Brainsway in the first quarter valued at $590,000. 30.11% of the stock is owned by institutional investors and hedge funds.

About Brainsway

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.